FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Inhousepharmacy Selling Illegal Unapproved Drugs: FDA

FDA warns inhousepharmacy.vu that it is illegally marketing domperidone drug products in the U.S.

Medical Devices

Dont Use Skippack Covid Rapid Test: FDA

FDA says the Skippack Medical Laboratory recall of rapid Covid-19 tests that were not cleared, approved, or authorized is Class 1 and people should no...

Biologics

Committee Documents Emergent Manufacturing Failures

A House committee staff report blasts Emergent Biosolutions for hiding its Covid-19 vaccine manufacturing problems from FDA and HHS.

Human Drugs

Lillys Olumiant Approved for Covid-19

FDA approves a new indication for Eli Lillys Olumiant (baricitinib) for treating Covid-19 in hospitalized adults requiring supplemental oxygen, non-in...

Biologics

CBER Ups Likely 2022 Guidances

CBER increases from 13 to 17 the number of guidances it expects to develop in 2022.

Medical Devices

FDA Needs More Digital Power: Patel

Former FDA Digital Health Center of Excellence director Bakul Patel says the agency needs additional congressional authorities to fully implement its ...

Federal Register

Glucotrol Not Withdrawn Due to Safety/Efficacy: FDA

Federal Register notice: FDA determines that Pfizers Glucotrol (glipizide) tablets, 2.5 mg, were not withdrawn from sale due to safety or effectivenes...

Federal Register

Drug Quality Assessments Guidance

Federal Register notice: FDA makes available a draft guidance entitled Benefit-risk Considerations for Product Quality Assessments.

Medical Devices

Draft Guide on Cybersecurity for Legacy Devices

The International Medical Device Regulators Forum (IMDRF), of which FDA is a member, seeks comments on a proposed guidance entitled Principles and Pra...

Biologics

FDA Not Delaying Pediatric Covid Vaccines: Marks

CBER director Peter Marks tells a House briefing that FDA is not delaying its review of Modernas Covid-19 vaccine for children under five years old so...